Physician profile
Mark A Hoffman
NPI 1164593257
$1,745.83
in general payments reported to CMS, 2019-2025
10 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.43 · 2021: $68.67 · 2022: $96.90 · 2023: $204 · 2024: $972 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773 · Long Term Medical Supply Or Device Loan: $682 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.30 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,287.59 | 2021-2025 | |
| Gilead Sciences, INC. | $144.53 | 2021-2025 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $110.27 | 2024-2025 | Myrisk |
| Celgene Corporation | $50.70 | 2022-2023 | Reblozyl |
| Medtronic USA, INC. | $36.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.29 | 2022-2025 | Reblozyl |
| Geron Corporation | $26.85 | 2025 | Rytelo |
| Janssen Biotech, INC. | $22.46 | 2025 | Darzalex, Talvey |
| Stemline Therapeutics INC. | $18.35 | 2024 | Orserdu |
| Alexion Pharmaceuticals, INC. | $16.36 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.